Vildagliptin, a DDP-4 inhibitor used in therapy for type 2 diabetes, has been shown to increase adiponectin levels, as well as to improve inflammatory biomarkers and LDL oxidation in obese diabetic patients [147]. Here, ADIPOQ is linked to type 2 diabetes mellitus.